Avalon GloboCare Forms Strategic Partnership with Major Biomedical Enterprise Da An Gene

Biotech Investing

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced that the Company has formed a strategic partnership with Da An Gene Co., Ltd, a major biomedical company publicly listed on the Shenzhen Stock Exchange (002030.SZ), to further optimize Avalon’s exosome-based technology, clinical development, as well as product commercialization. As quoted in the press …

Avalon GloboCare (OTCQB: AVCO), a leading global developer of cell-based technologies, announced that the Company has formed a strategic partnership with Da An Gene Co., Ltd, a major biomedical company publicly listed on the Shenzhen Stock Exchange (002030.SZ), to further optimize Avalon’s exosome-based technology, clinical development, as well as product commercialization.
As quoted in the press release:

“This strategic partnership with Da An Gene will significantly accelerate our product development and commercialization in the fields of liquid biopsy and in vitro diagnostics,” said David Jin, M.D., Ph.D., President and CEO of Avalon GloboCare, as well as co-CEO of its subsidiary GenExosome Technologies Inc. “The specialty of Da An’s genomic sequencing and profiling platform, in combination with our proprietary exosome isolation system and clinical expertise in regenerative medicine, will further establish Avalon’s leading role in precision and regenerative medicine,” added Dr. Jin.

Click here to read the full press release.

The Conversation (0)
×